Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Current Editions
Non-GAAP profitability in sight as RNAi therapeutic adds cardiomyopathy indication alongside previous amyloidosis approval
Regulation
Product Development
How Vertex is translating its success from CF into new areas, picking indication by indication, while leveraging AI
Editor's Commentary
Epigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery
Data Byte
After a takeout is announced, the target company’s share price hews much closer to the deal price without the CVR than with it
Management Tracks
Plus: Hyku names Keith Wilcoxen CSO and new CMO at Immuneering
BioCentury ISSN 1097-7201